Related Experiment Video

Updated: Jun 23, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Inhibition of HGF/MET as therapy for malignancy

Sanjay Naran1, Xinglu Zhang, Steven J Hughes

  • 1University of Pittsburgh School of Medicine, Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA 15261, USA.

Expert Opinion on Therapeutic Targets
|April 29, 2009
PubMed
Abstract

Insights

Targeting the hepatocyte growth factor (HGF)/Mesenchymal-epithelial transition factor (MET) pathway shows promise for cancer treatment. MET inhibitors are nearing clinical use, offering a new therapeutic strategy for malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Malignancy often involves dysregulated tyrosine kinase activity.
  • Targeting specific signaling pathways is a key cancer treatment strategy.

Purpose of the Study:

  • To review the role of the HGF/MET pathway in cancer.
  • To evaluate MET pathway inhibition as a cancer therapy.

Main Methods:

  • Literature review of HGF/MET pathway structure and function.
  • Analysis of current MET inhibitors and their clinical development status.

Main Results:

  • The HGF/MET pathway is implicated in cancer development.
  • Inhibiting this pathway presents a viable therapeutic approach.

Conclusions:

  • HGF/MET pathway inhibition demonstrates significant potential for cancer treatment.
  • Several MET inhibitors are in late-stage development for clinical application.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...